CISPLATINE VIATRIS 25 mg/25 ml clinical trials

OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS

This study looks at how long immunotherapy works for people with advanced lung cancer and how it affects their bodies. We're testing different drug combinations to see which works best and for how long, to improve treatment plans.